Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Specific inhibition of microsomal Prostaglandin E synthesis, safety pharmacology advantage over NSAIDs?

Reference number
Coordinator Gesynta Pharma AB
Funding from Vinnova SEK 1 000 000
Project duration June 2018 - May 2019
Status Completed

Purpose and goal

Gesynta Pharma AB, together with expertise from Swetox / RISE, investigated cardiovascular safety of the drug candidate GS-248. The microsomal Prostaglandin E synthase-1 inhibitor GS-248 had no adverse effect on cardiovascular function in a regulatory pharmacological animal model.

Expected effects and result

The result has provided a basis for continued funding up to, and including, Phase 1. In addition, the results have been included in an approved Phase 1 application to the Swedish Medical Products Agency. The Phase 1 study thus initiated will constitute the company´s main asset in the event of a possible out-licensing or sale.

Planned approach and implementation

A contract laboratory (LPT Laboratory of Pharmacology and Toxicology GmbH & Co.) conducted the cardiovascular safety study, which was evaluated by Swetox / RISE expertise. Analysis of samples, treatment of data from studies, as well as presentation of data for authorities, investors and potential partners has been performed by Gesynta, KI and RISE.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 January 2019

Reference number 2018-00228

Page statistics